Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
出版信息
Liver Cancer. 2018 Sep;7(3):225-234. doi: 10.1159/000492535. Epub 2018 Aug 23.
Abstract
摘要
相似文献
1
Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial.经动脉化疗栓塞术联合全身治疗试验的主要终点建议：从5项阴性试验和阳性TACTICS试验中吸取的经验教训
Liver Cancer. 2018 Sep;7(3):225-234. doi: 10.1159/000492535. Epub 2018 Aug 23.
2
Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).经动脉化疗栓塞联合分子靶向药物：从阴性试验（TACE后、BRISK-TA、SPACE、ORIENTAL和TACE-2）中吸取的教训
Oncology. 2017;93 Suppl 1:127-134. doi: 10.1159/000481243. Epub 2017 Dec 20.
3
Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): a randomized controlled trial.对比立体定向消融放疗（SABR）与再次经导管动脉化疗栓塞术（re-TACE）治疗初始 TACE 后不完全缓解的肝细胞癌患者（TASABR）：一项随机对照试验。
BMC Cancer. 2019 Mar 28;19(1):275. doi: 10.1186/s12885-019-5461-3.
4
Percutaneous ethanol injection for liver metastases.经皮乙醇注射治疗肝转移瘤
Cochrane Database Syst Rev. 2013 May 31(5):CD008717. doi: 10.1002/14651858.CD008717.pub2.
5
Clinical trials in systemic sclerosis: lessons learned and outcomes.系统性硬化症的临床试验：经验教训与结果
Arthritis Res Ther. 2007;9 Suppl 2(Suppl 2):S7. doi: 10.1186/ar2191.
6
To TACE or not to TACE? Lessons from a negative trial.做经动脉化疗栓塞术还是不做？来自一项阴性试验的经验教训。
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):541-543. doi: 10.1016/S2468-1253(17)30181-4. Epub 2017 Jun 23.
7
Arsenic trioxide combined with transarterial chemoembolization for primary liver cancer: A meta-analysis.三氧化二砷联合经动脉化疗栓塞治疗原发性肝癌：一项荟萃分析。
J Gastroenterol Hepatol. 2017 Sep;32(9):1540-1547. doi: 10.1111/jgh.13789.
8
The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.经导管动脉化疗栓塞术联合索拉非尼在亚洲肝细胞癌患者中具有良好的耐受性和疗效：START 试验的最终结果。
Int J Cancer. 2015 Mar 15;136(6):1458-67. doi: 10.1002/ijc.29126. Epub 2014 Sep 16.
9
[Survival benefit with intraarterial techniques in hepatocellular carcinoma].[肝细胞癌动脉内治疗技术的生存获益]
Gastroenterol Hepatol. 2014 Jul;37 Suppl 2:95-101. doi: 10.1016/S0210-5705(14)70076-7.
10
An efficient method for accommodating potentially underpowered primary endpoints.一种用于处理潜在低效能主要终点的有效方法。
Stat Med. 2008 Nov 20;27(26):5377-91. doi: 10.1002/sim.3369.
引用本文的文献
1
2
Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma.经动脉化疗栓塞联合卡瑞利珠单抗和瑞沃替尼与单纯卡瑞利珠单抗和瑞沃替尼治疗BCLC C期肝细胞癌的比较
J Hepatocell Carcinoma. 2024 Dec 20;11:2515-2524. doi: 10.2147/JHC.S494520. eCollection 2024.
3
Challenges in Adjuvant Immunotherapy after Resection or Ablation for Hepatocellular Carcinoma at High-Risk of Recurrence.肝细胞癌切除或消融术后复发高危患者辅助免疫治疗面临的挑战
Liver Cancer. 2024 Oct 24;13(6):573-578. doi: 10.1159/000542221. eCollection 2024 Dec.
4
Immune Checkpoint Inhibitors plus Anti-VEGF/Tyrosine Kinase Inhibitors Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma.免疫检查点抑制剂加抗血管内皮生长因子/酪氨酸激酶抑制剂联合经动脉化疗栓塞术（三联疗法）治疗不可切除肝细胞癌
Liver Cancer. 2024 Apr 17;13(3):227-234. doi: 10.1159/000538558. eCollection 2024 Jun.
5
Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate-stage Hepatocellular Carcinoma: A Multicenter Retrospective Study.经动脉化疗栓塞联合阿替利珠单抗加贝伐单抗与单纯经动脉化疗栓塞治疗中期肝细胞癌的多中心回顾性研究
J Hepatocell Carcinoma. 2024 Jun 12;11:1079-1093. doi: 10.2147/JHC.S461630. eCollection 2024.
6
The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.PD-1 抑制剂联合 TACE 用于不可切除肝细胞癌一线治疗的疗效和安全性。
Med Oncol. 2024 Mar 25;41(5):91. doi: 10.1007/s12032-024-02309-5.
7
New Insights on Liver-Directed Therapies in Hepatocellular Carcinoma.肝细胞癌肝靶向治疗的新见解
Cancers (Basel). 2023 Dec 8;15(24):5749. doi: 10.3390/cancers15245749.
8
Pathologic Complete Response After Gastric Artery Chemoembolization Combined With Tislelizumab for Neoadjuvant Therapy of Locally Advanced Gastric Cancer: A Case Report.胃动脉化疗栓塞联合替雷利珠单抗新辅助治疗局部进展期胃癌后病理完全缓解：1 例报告。
J Immunother. 2024 Apr 1;47(3):101-105. doi: 10.1097/CJI.0000000000000488. Epub 2023 Nov 23.
9
Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.TACE 联合卡瑞利珠单抗和阿帕替尼治疗 HCC（CHANCE2211）的真实世界疗效和安全性：一项倾向评分匹配研究。
Eur Radiol. 2023 Dec;33(12):8669-8681. doi: 10.1007/s00330-023-09754-2. Epub 2023 Jun 27.
10
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001).经动脉化疗栓塞术联合 PD-(L)1 抑制剂和分子靶向治疗肝癌（CHANCE001）。
Signal Transduct Target Ther. 2023 Feb 8;8(1):58. doi: 10.1038/s41392-022-01235-0.
本文引用的文献
1
Validation of Newly Proposed Time to Transarterial Chemoembolization Progression in Intermediate-Stage Hepatocellular Carcinoma Cases.中期肝细胞癌病例中新提出的经动脉化疗栓塞进展时间的验证
Oncology. 2017;93 Suppl 1:120-126. doi: 10.1159/000481242. Epub 2017 Dec 20.
2
Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).经动脉化疗栓塞联合分子靶向药物：从阴性试验（TACE后、BRISK-TA、SPACE、ORIENTAL和TACE-2）中吸取的教训
Oncology. 2017;93 Suppl 1:127-134. doi: 10.1159/000481243. Epub 2017 Dec 20.
3
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.不可切除肝细胞癌患者重复经动脉化疗栓塞术期间的肝功能及引入索拉非尼后的预后：多中心分析
Dig Dis. 2017;35(6):602-610. doi: 10.1159/000480256. Epub 2017 Oct 17.
4
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.奥仑替尼与安慰剂联合经导管动脉化疗栓塞治疗不可切除肝细胞癌患者（ORIENTAL）：一项随机、双盲、安慰剂对照、多中心、3 期研究。
Lancet Gastroenterol Hepatol. 2018 Jan;3(1):37-46. doi: 10.1016/S2468-1253(17)30290-X. Epub 2017 Oct 4.
5
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.索拉非尼联合经动脉化疗栓塞治疗不可切除肝细胞癌（TACE 2）：一项随机安慰剂对照、双盲、3 期临床试验。
Lancet Gastroenterol Hepatol. 2017 Aug;2(8):565-575. doi: 10.1016/S2468-1253(17)30156-5. Epub 2017 Jun 23.
6
The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization.肝细胞癌患者的总生存期与经动脉化疗栓塞术后新定义的疾病进展时间相关。
Liver Cancer. 2017 Jun;6(3):227-235. doi: 10.1159/000475777. Epub 2017 May 9.
7
Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.肝细胞癌的分子靶向药物：现状与未来展望
Liver Cancer. 2017 Feb;6(2):101-112. doi: 10.1159/000452138. Epub 2016 Dec 15.
8
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.肝细胞癌中的免疫检查点阻断：2017年更新
Liver Cancer. 2016 Nov;6(1):1-12. doi: 10.1159/000449342. Epub 2016 Nov 29.
9
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2016 Apr 14;2:16018. doi: 10.1038/nrdp.2016.18.
10
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.索拉非尼或安慰剂联合载多柔比星微球 TACE 治疗中晚期 HCC：SPACE 试验。
J Hepatol. 2016 May;64(5):1090-1098. doi: 10.1016/j.jhep.2016.01.012. Epub 2016 Jan 22.
Zotero 插件